About Design Therapeutics
Design Therapeutics is a company based in Carlsbad (United States) founded in 2006 by Aseem Ansari.. Design Therapeutics has raised $170.5 million across 5 funding rounds from investors including BlackRock, Citadel and Janus Henderson Investors. The company has 54 employees as of December 31, 2024. Design Therapeutics offers products and services including GeneTAC Platform, Friedreich Ataxia Program, Fuchs Endothelial Corneal Dystrophy Program, Myotonic Dystrophy Program, and Huntington’s Disease Program. Design Therapeutics operates in a competitive market with competitors including BridgeBio, Moderna, Spark Therapeutics, Mereo BioPharma and Amicus Therapeutics, among others.
- Headquarter Carlsbad, United States
- Employees 54 as on 31 Dec, 2024
- Founders Aseem Ansari
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Design Therapeutics, Inc.
-
Annual Revenue
$00as on Dec 31, 2024
-
Net Profit
$-49.59 M25.84as on Dec 31, 2024
-
EBITDA
$-61.79 M20.43as on Dec 31, 2024
-
Total Equity Funding
$170.5 M (USD)
in 5 rounds
-
Latest Funding Round
$125 M (USD), Series B
Jan 27, 2021
-
Investors
BlackRock
& 9 more
-
Employee Count
54
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Design Therapeutics
Design Therapeutics is a publicly listed company on the NASDAQ with ticker symbol DSGN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Design Therapeutics
Design Therapeutics offers a comprehensive portfolio of products and services, including GeneTAC Platform, Friedreich Ataxia Program, Fuchs Endothelial Corneal Dystrophy Program, Myotonic Dystrophy Program, and Huntington’s Disease Program. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Platform for developing small molecule therapies targeting genetic disorders.
Program advancing treatments for Friedreich ataxia genetic disease.
Program for therapies targeting Fuchs endothelial corneal dystrophy.
Program developing treatments for myotonic dystrophy disorder.
Program focused on therapies for Huntington’s disease patients.
Unlock access to complete
Unlock access to complete
Funding Insights of Design Therapeutics
Design Therapeutics has successfully raised a total of $170.5M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $125 million completed in January 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Series B — $125.0M
-
First Round
First Round
(07 Jan 2019)
- Investors Count 10
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2021 | Amount | Series B - Design Therapeutics | Valuation | Logos | |
| Jun, 2020 | Amount | Series A - Design Therapeutics | Valuation | SR One , Quan Capital |
|
| Jul, 2019 | Amount | Grant - Design Therapeutics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Design Therapeutics
Design Therapeutics has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include BlackRock, Citadel and Janus Henderson Investors. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity fund focused on the biotechnology sector
|
Founded Year | Domain | Location | |
|
A biotechnology venture capital firm investing in innovative science.
|
Founded Year | Domain | Location | |
|
Investments are directed toward early and growth stage companies.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Design Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Design Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Design Therapeutics Comparisons
Competitors of Design Therapeutics
Design Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Moderna, Spark Therapeutics, Mereo BioPharma and Amicus Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for cancer and rare diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of therapies for rare and orphan diseases
|
|
| domain | founded_year | HQ Location |
Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Design Therapeutics
Frequently Asked Questions about Design Therapeutics
When was Design Therapeutics founded?
Design Therapeutics was founded in 2006 and raised its 1st funding round 13 years after it was founded.
Where is Design Therapeutics located?
Design Therapeutics is headquartered in Carlsbad, United States. It is registered at Carlsbad, California, United States.
Is Design Therapeutics a funded company?
Design Therapeutics is a funded company, having raised a total of $170.5M across 5 funding rounds to date. The company's 1st funding round was a Grant of $225K, raised on Jan 07, 2019.
How many employees does Design Therapeutics have?
As of Dec 31, 2024, the latest employee count at Design Therapeutics is 54.
What does Design Therapeutics do?
Design Therapeutics was founded in 2006 and is based in Carlsbad, United States. Focus is placed on biotechnology within the pharmaceutical sector, where disease-modifying therapies for degenerative disorders are developed. Operations involve research and clinical development of targeted treatments. The companys domain, designtx.com, supports these activities. Co-founder Aseem Ansari contributes to strategic direction in this field.
Who are the top competitors of Design Therapeutics?
Design Therapeutics's top competitors include Moderna, Spark Therapeutics and BridgeBio.
What products or services does Design Therapeutics offer?
Design Therapeutics offers GeneTAC Platform, Friedreich Ataxia Program, Fuchs Endothelial Corneal Dystrophy Program, Myotonic Dystrophy Program, and Huntington’s Disease Program.
Is Design Therapeutics publicly traded?
Yes, Design Therapeutics is publicly traded on NASDAQ under the ticker symbol DSGN.
Who are Design Therapeutics's investors?
Design Therapeutics has 10 investors. Key investors include BlackRock, Citadel, Janus Henderson Investors, RA Capital, and Logos Capital.
What is Design Therapeutics's ticker symbol?
The ticker symbol of Design Therapeutics is DSGN on NASDAQ.